Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin A secretion (process) (IgA secretion)
- Target
- IgA secretion
- Molecular classification
- Other (as a process: secretion), Antibody (the actual molecule: immunoglobulin), Receptor (for involved proteins: polymeric immunoglobulin receptor (pIgR), FcαRI (CD89))
01
Overview
Immunoglobulin A secretion describes the process by which IgA antibodies, produced by plasma cells in the lamina propria, are transported across epithelial cells and released as secretory IgA (sIgA) into mucosal surfaces, such as the gastrointestinal, respiratory, and genitourinary tracts. This is mediated by the polymeric immunoglobulin receptor (pIgR), which binds dimeric IgA and transcytoses it, with the secretory component protecting sIgA from degradation. sIgA acts as a primary barrier against pathogens by neutralizing toxins and viruses, trapping microbes in mucus, blocking receptor access, and downregulating inflammation. Its deficiency increases susceptibility to mucosal infections, and IgA or its receptors are of interest for therapeutic development, though no drugs currently target "IgA secretion" itself.
- Other names
- Secretory immunoglobulin A (sIgA)IgASecretory antibody
02
Mechanism of action
Not directly applicable; for IgA or its receptors, mechanisms include antibody-dependent cellular cytotoxicity, phagocytosis, neutralization of pathogens, receptor blockade, and immune exclusion
03
Biological functions
Immune responseMucosal immunityNeutralization of pathogens and toxinsImmune exclusion (agglutination and clearance of antigens)Anti-inflammatory regulation
04
Disease associations
Infection (first defense against pathogens at mucosal surfaces)InflammationImmunodeficiency (selective IgA deficiency leads to increased mucosal infection risk)Autoimmune disease (abnormal IgA responses can contribute)Other (e.g., some cancers via dysregulation)
05
Safety considerations
IgA deficiency can predispose to recurrent infectionsAbnormal IgA responses implicated in some autoimmune and inflammatory disordersTherapeutic challenges include stability of IgA-based drugs and targeting its receptors without off-target inflammation
06
Interacting drugs
None directly target IgA secretion as a therapeutic endpoint; however, research into monoclonal IgA antibodies and inhibitors of the FcαRI receptor is ongoing
07
Biomarkers
Serum IgA levels (for immunodeficiency diagnosis or infection monitoring)sIgA concentration in secretions (saliva, stool, etc.)
Beyond the preview
Go deeper on Immunoglobulin A secretion (process) (IgA secretion).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin A secretion (process) (IgA secretion).